Compounds > ah 6809
Page last updated: 2024-09-25

ah 6809

Description

6-isopropoxy-9-oxoxanthene-2-carboxylic acid: structure given in UD [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119461
CHEMBL ID1317823
CHEBI ID95289
SCHEMBL ID1163801
MeSH IDM0152428

Synonyms (44)

Synonym
6-isopropoxy-9-oxo-9h-xanthene-2-carboxylic acid
HMS3266H17
BRD-K59339270-001-01-8
gtpl1896
tocris-0671
NCGC00024721-01
PDSP2_001532
PDSP1_001548
ah6809
6-(1-methylethoxy)-9-oxo-9h-xanthene-2-carboxylic acid
ah 6809
6-isopropoxy-9-oxoxanthene-2-carboxylic acid
9h-xanthene-2-carboxylic acid, 6-(1-methylethoxy)-9-oxo-
ah-6809
33458-93-4
L000101
9-oxo-6-propan-2-yloxyxanthene-2-carboxylic acid
bdbm85184
cas_33458-93-4
nsc_119461
CS-1549
HY-10418
SCHEMBL1163801
6-isopropoxy-9-xanthone-2-carboxylic acid
AQFFXPQJLZFABJ-UHFFFAOYSA-N
AKOS024458601
CHEMBL1317823
HMS3648F13
ah6809, >=98%, crystalline solid or supercooled liquid
DTXSID80187106
sr-01000597664
SR-01000597664-1
CHEBI:95289
J-019193
HMS3675O12
Q27074359
SR-01000597664-2
HMS3411O12
EX-A7711
A913344
BS-52004
6-isopropoxy-9-xanthone-2-carboxylicacid
9-oxo-6-(propan-2-yloxy)-9h-xanthene-2-carboxylic acid
E85579

Drug Classes (1)

ClassDescription
xanthonesAny member of the class of xanthenes based on a xanthone skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.00080.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency15.84890.316212.443531.6228AID902
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency39.81070.001815.663839.8107AID894
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E2 receptor EP1 subtypeHomo sapiens (human)Ki1.20000.00910.66351.5849AID1151378
Prostaglandin E2 receptor EP4 subtypeHomo sapiens (human)Ki100.00000.00010.47443.1623AID1151380
Prostaglandin E2 receptor EP3 subtypeHomo sapiens (human)Ki1.60000.00031.70816.8000AID1151379
Prostaglandin E2 receptor EP2 subtypeHomo sapiens (human)Ki1.15000.00100.54483.0000AID1151377; AID1151383
Prostacyclin receptorHomo sapiens (human)Ki100.00000.00320.49586.6280AID1151382
Prostaglandin D2 receptorHomo sapiens (human)Ki1.40000.00060.49131.4000AID1151381
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
response to lipopolysaccharideProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
negative regulation of cytokine productionProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
positive regulation of cytokine productionProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
immune responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
JNK cascadeProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
response to mechanical stimulusProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
response to nematodeProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
regulation of ossificationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
response to lipopolysaccharideProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
negative regulation of integrin activationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
T-helper cell differentiationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
negative regulation of inflammatory responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
positive regulation of inflammatory responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
regulation of stress fiber assemblyProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
bone developmentProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
ERK1 and ERK2 cascadeProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
cellular response to mechanical stimulusProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
negative regulation of eosinophil extravasationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
cellular response to prostaglandin E stimulusProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
cell deathProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
positive regulation of fever generationProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
intestine smooth muscle contractionProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
negative regulation of gastric acid secretionProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
response to nematodeProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
response to lipopolysaccharideProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
response to progesteroneProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
regulation of cell population proliferationProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
cellular response to prostaglandin E stimulusProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerProstacyclin receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstacyclin receptorHomo sapiens (human)
cell-cell signalingProstacyclin receptorHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayProstacyclin receptorHomo sapiens (human)
response to lipopolysaccharideProstacyclin receptorHomo sapiens (human)
negative regulation of smooth muscle cell proliferationProstacyclin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstacyclin receptorHomo sapiens (human)
inflammatory responseProstacyclin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin D2 receptorHomo sapiens (human)
male sex determinationProstaglandin D2 receptorHomo sapiens (human)
sleepProstaglandin D2 receptorHomo sapiens (human)
mast cell degranulationProstaglandin D2 receptorHomo sapiens (human)
adenosine metabolic processProstaglandin D2 receptorHomo sapiens (human)
cellular response to prostaglandin D stimulusProstaglandin D2 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin D2 receptorHomo sapiens (human)
inflammatory responseProstaglandin D2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
D1 dopamine receptor bindingProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
protein bindingProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
guanyl-nucleotide exchange factor activityProstacyclin receptorHomo sapiens (human)
prostacyclin receptor activityProstacyclin receptorHomo sapiens (human)
prostaglandin J receptor activityProstaglandin D2 receptorHomo sapiens (human)
prostaglandin D receptor activityProstaglandin D2 receptorHomo sapiens (human)
protein bindingProstaglandin D2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
membraneProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
nuclear envelopeProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
membraneProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
cytosolProstacyclin receptorHomo sapiens (human)
plasma membraneProstacyclin receptorHomo sapiens (human)
plasma membraneProstacyclin receptorHomo sapiens (human)
plasma membraneProstaglandin D2 receptorHomo sapiens (human)
membraneProstaglandin D2 receptorHomo sapiens (human)
plasma membraneProstaglandin D2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1151377Antagonist activity at EP2 receptor (unknown origin) by functional cAMP assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Prostanoid receptor EP2 as a therapeutic target.
AID1151378Antagonist activity at EP1 receptor (unknown origin) by functional cAMP assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Prostanoid receptor EP2 as a therapeutic target.
AID1151380Antagonist activity at EP4 receptor (unknown origin) by functional cAMP assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Prostanoid receptor EP2 as a therapeutic target.
AID1151382Antagonist activity at prostanoid IP receptor (unknown origin) by functional cAMP assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Prostanoid receptor EP2 as a therapeutic target.
AID1151379Antagonist activity at EP3 receptor (unknown origin) by functional cAMP assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Prostanoid receptor EP2 as a therapeutic target.
AID1151383Inhibition of EP2 receptor (unknown origin) by competitive binding assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Prostanoid receptor EP2 as a therapeutic target.
AID1151381Antagonist activity at DP1 receptor (unknown origin) by functional cAMP assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Prostanoid receptor EP2 as a therapeutic target.
AID1346343Human EP3 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346377Human DP1 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346408Human EP1 receptor (Prostanoid receptors)2002The Journal of pharmacy and pharmacology, Apr, Volume: 54, Issue:4
Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques.
AID1346303Mouse EP2 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346308Human EP2 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346345Rat EP1 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346318Rat EP2 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346408Human EP1 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (159)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (1.89)18.7374
1990's39 (24.53)18.2507
2000's62 (38.99)29.6817
2010's50 (31.45)24.3611
2020's5 (3.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.61%)5.53%
Reviews2 (1.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other160 (98.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
bw 245c[no description available]medium70imidazolidine-2,4-dione;
monocarboxylic acid;
secondary alcohol
bw a868c[no description available]medium20imidazolidine-2,4-dione
prostaglandin d2[no description available]medium200prostaglandins Dhuman metabolite;
mouse metabolite
dinoprostone[no description available]medium1200prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprostone[no description available]medium1201prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost[no description available]medium180monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
alprostadil[no description available]medium310prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
11-deoxyprostaglandin e1[no description available]medium20prostanoid
16,16-dimethylprostaglandin e2[no description available]medium20cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol		anti-ulcer drug;
gastrointestinal drug;
radiation protective agent
17-phenyltrinorprostaglandin e2[no description available]medium30alicyclic ketone;
beta-hydroxy ketone;
hydroxy monocarboxylic acid;
olefinic compound;
oxo monocarboxylic acid;
prostanoid;
secondary alcohol		human metabolite;
prostaglandin receptor agonist
ah 13205[no description available]medium40
cicaprost[no description available]medium40monoterpenoid
fluprostenol[no description available]medium30(trifluoromethyl)benzenes;
hydroxy monocarboxylic acid;
prostaglandins Falpha		abortifacient;
antiglaucoma drug;
antihypertensive agent;
female contraceptive drug;
prostaglandin receptor agonist
m&b 28,767[no description available]medium30
u-44619[no description available]medium30
s 145[no description available]medium10monoterpenoid
sulprostone[no description available]medium160prostanoid
ono 1301[no description available]medium10
sq 28053[no description available]medium20
19-hydroxyprostaglandin e1[no description available]medium10
vapiprost[no description available]medium50
sc-19220[no description available]medium20aromatic ether
ah 23848[no description available]medium210(4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid
enprostil[no description available]medium40
ono 8713[no description available]medium10
misoprostol[no description available]medium90
cloprostenol[no description available]medium30prostanoid
latanoprost[no description available]medium10isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
misoprostol acid[no description available]medium10
phxa 85[no description available]medium10hydroxy monocarboxylic acid;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
epoprostenol[no description available]medium10prostaglandins Imouse metabolite
2-[[2-furanyl(oxo)methyl]amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid ethyl ester[no description available]medium10organosulfur heterocyclic compound
butaprost[no description available]medium10
tg4-155[no description available]medium10
cp533536[no description available]medium10monocarboxylic acid
cp 544326[no description available]medium10
pf-04418948[no description available]medium10
tg6-10-1[no description available]medium10
butaprost[no description available]medium210
alpha-aminopyridine[no description available]medium10
ribociclib[no description available]medium10
bay 11-7082[no description available]medium10nitrile;
sulfone		apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor
celecoxib[no description available]medium50organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
interleukin-8[no description available]medium40
pyrrolidonecarboxylic acid[no description available]medium105-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
gamma-aminobutyric acid[no description available]medium20amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
nickel sulfate[no description available]medium10metal sulfateallergen
nickel[no description available]medium10metal allergen;
nickel group element atom		epitope;
micronutrient
pd 98059[no description available]medium10aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
semaxinib[no description available]medium10olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
pyrroles[no description available]medium40pyrrole;
secondary amine
l-161982[no description available]medium60biphenyls
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide[no description available]medium110aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor
thiophenes[no description available]medium80mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
triazoles[no description available]medium601,2,3-triazole
palmitic acid[no description available]medium10long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
ng-nitroarginine methyl ester[no description available]medium50alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
nimesulide[no description available]medium10aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
glyceryl 2-arachidonate[no description available]medium102-acylglycerol 20:4;
endocannabinoid		human metabolite
muscarine[no description available]medium10monosaccharide
capsaicin[no description available]medium20capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
dup 697[no description available]medium20thiophenes
capsazepine[no description available]medium20benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole[no description available]medium10benzoic acid;
imidazolines;
organic radical		apoptosis inhibitor;
radical scavenger
arachidonic acid[no description available]medium30icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
quinazolines[no description available]medium10azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
saracatinib[no description available]medium10aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
cay 10580[no description available]medium10hydroxy monocarboxylic acid;
pyrrolidin-2-ones;
secondary alcohol		prostaglandin receptor agonist
ondansetron[no description available]medium10carbazoles
kt 5720[no description available]medium30carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
hydrazine[no description available]medium121azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
sc 51089[no description available]medium41
thromboplastin[no description available]medium11
fluorouracil[no description available]medium10nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
indomethacin[no description available]medium180aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
oxytocin[no description available]medium10heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
taprostene[no description available]medium10benzoic acids
leukotriene b4[no description available]medium20dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
l 663536[no description available]medium10aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
mifepristone[no description available]medium103-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
mk-0524[no description available]medium10indolyl carboxylic acid
ethacrynic acid[no description available]medium10aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
15-deoxyprostaglandin j2[no description available]medium10
acetylcysteine[no description available]medium10acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
colforsin[no description available]medium50acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
ethylmaleimide[no description available]medium10maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
hydantoins[no description available]medium70imidazolidine-2,4-dione
milrinone[no description available]medium10bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
isoproterenol[no description available]medium40catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
sq 29548[no description available]medium90
1-ethyl-2-benzimidazolinone[no description available]medium10imidazoles
7-nitroindazole[no description available]medium20
methionine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
bradykinin[no description available]medium50oligopeptidehuman blood serum metabolite;
vasodilator agent
cardiovascular agents[no description available]medium10
indazoles[no description available]medium20indazole
ketamine[no description available]medium10cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
angiotensin ii[no description available]medium10amino acid zwitterion;
angiotensin II		human metabolite
glycine[no description available]medium10alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
flurbiprofen[no description available]medium20fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
glutamine[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
glutamic acid[no description available]medium30glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
8-isoprostaglandin e2[no description available]medium20cyclic ketone;
diol;
prostanoid;
secondary alcohol		bronchoconstrictor agent;
human metabolite;
rat metabolite;
vasoconstrictor agent
furegrelate[no description available]medium10benzofurans
benzofurans[no description available]medium20
dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide[no description available]medium140
al 8810[no description available]medium20long-chain fatty acid
atrial natriuretic factor[no description available]medium10polypeptide
naproxen[no description available]medium30methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
2-methyl-5-ht[no description available]medium10tryptaminesserotonergic agonist
dimethyl sulfoxide[no description available]medium30sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
cyclopentane[no description available]medium10cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
ro3244794[no description available]medium10
wortmannin[no description available]medium10acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
cycloheximide[no description available]medium10antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
h 89[no description available]medium70N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
adenine[no description available]medium106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
9-(tetrahydro-2-furyl)-adenine[no description available]medium10
tetradecanoylphorbol acetate[no description available]medium10acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
ono ae 248[no description available]medium10
ono-ae1-329[no description available]medium10
ono-di-004[no description available]medium10
tetrodotoxin[no description available]medium50azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
cuprizone[no description available]medium10organonitrogen compound;
organooxygen compound
fluorescein-5-isothiocyanate[no description available]medium10fluorescein isothiocyanate
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid[no description available]medium160
ici 192605[no description available]medium30
thromboxanes[no description available]medium40
carbachol[no description available]medium20ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
piperidines[no description available]medium10
l 733060[no description available]medium10piperidines
substance p[no description available]medium10peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
vitamin k 3[no description available]medium101,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
alpha-linolenic acid[no description available]medium10linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical
lipoxin a4[no description available]medium10hydroxy polyunsaturated fatty acid;
lipoxin;
long-chain fatty acid		human metabolite;
metabolite
resolvin d2[no description available]medium10hydroxy polyunsaturated fatty acid;
resolvin;
secondary allylic alcohol;
triol		anti-inflammatory agent;
anti-obesity agent;
estrogen receptor agonist;
human xenobiotic metabolite;
rat metabolite
resolvin d1[no description available]medium10hydroxy polyunsaturated fatty acid;
resolvin;
triol		anti-inflammatory agent
thromboxane a2[no description available]medium80epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite
ro 31-8220[no description available]medium10imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
cyclic gmp[no description available]medium103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
u 73122[no description available]medium20aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
ucn 1028 c[no description available]medium10
xanthenes[no description available]medium600xanthene
u 73343[no description available]medium10
prostaglandin a2[no description available]medium10prostaglandins Ahuman metabolite
yohimbine[no description available]medium30methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
leukotriene d4[no description available]medium30dipeptide;
leukotriene;
organic sulfide		bronchoconstrictor agent;
human metabolite;
mouse metabolite
iloprost[no description available]medium70carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
1-amino-1,3-dicarboxycyclopentane[no description available]medium10
2-amino-5-phosphonovalerate[no description available]medium10non-proteinogenic alpha-amino acidNMDA receptor antagonist
cycloleucine[no description available]medium10non-proteinogenic alpha-amino acidEC 2.5.1.6 (methionine adenosyltransferase) inhibitor
quisqualic acid[no description available]medium10non-proteinogenic alpha-amino acid
valine[no description available]medium10L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
8-bromo cyclic adenosine monophosphate[no description available]medium203',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist
nitroarginine[no description available]medium10guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
6-ketoprostaglandin f1 alpha[no description available]medium10prostaglandins Falphahuman metabolite;
mouse metabolite
diclofenac[no description available]medium10amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
aspirin[no description available]medium10benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
loxoprofen[no description available]medium10cyclopentanones;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
calpain[no description available]medium10
framycetin[no description available]medium10aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
pimagedine[no description available]medium10guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
nifedipine[no description available]medium20C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
adenosine-3',5'-cyclic phosphorothioate[no description available]medium10nucleoside 3',5'-cyclic phosphorothioate
phenyl acetate[no description available]medium10benzenes;
phenyl acetates
formaldehyde[no description available]medium10aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
l-826266[no description available]medium10
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine[no description available]medium101,2-diacyl-sn-glycero-3-phosphocholine;
aldehyde		apoptosis inducer
phosphatidylcholines[no description available]medium101,2-diacyl-sn-glycero-3-phosphocholine
icatibant[no description available]medium10
n-(3-(aminomethyl)benzyl)acetamidine[no description available]medium10aralkylamine;
carboxamidine;
primary amino compound		angiogenesis inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector
iberiotoxin[no description available]medium10
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole[no description available]medium10ether;
imidazoles;
monomethoxybenzene		TRP channel blocker
2-aminoethoxydiphenyl borate[no description available]medium10organoboron compound;
primary amino compound		calcium channel blocker;
IP3 receptor antagonist;
potassium channel opener
charybdotoxin[no description available]medium20
cortisone[no description available]medium1011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
potassium chloride[no description available]medium10inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
phenylephrine[no description available]medium10phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
ramatroban[no description available]medium30organic molecular entity
terutroban[no description available]medium10
inositol 1,4,5-trisphosphate[no description available]medium20myo-inositol trisphosphatemouse metabolite
l 670596[no description available]medium10carbazoles
gr 63799x[no description available]medium20
apomorphine[no description available]medium10aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
melatonin[no description available]medium10acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
m&b 28,767[no description available]medium20
glucose, (beta-d)-isomer[no description available]medium10D-glucopyranoseepitope;
mouse metabolite
n-formylmethionine leucyl-phenylalanine[no description available]medium10tripeptide
1-hexadecyl-2-acetyl-glycero-3-phosphocholine[no description available]medium302-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
8-epi-prostaglandin f2alpha[no description available]medium20F2-isoprostanebiomarker;
bronchoconstrictor agent;
vasoconstrictor agent
prostaglandin e3[no description available]medium10prostaglandins Ehuman metabolite
erythrosine[no description available]medium10
oxotremorine[no description available]medium10N-alkylpyrrolidine
scopolamine hydrobromide[no description available]medium10
alpha-methylhistamine[no description available]medium10aralkylamino compound;
imidazoles		animal metabolite;
H3-receptor agonist
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
sodium selenite[no description available]medium10inorganic sodium salt;
selenite salt		nutraceutical
histamine[no description available]medium10aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
cv 3988[no description available]medium10
pf 5901[no description available]medium10quinolines
adenosine monophosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
arachidonyltrifluoromethane[no description available]medium10fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound		EC 3.1.1.4 (phospholipase A2) inhibitor
beta-alanine[no description available]medium10amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
l 745337[no description available]medium10
2,2-dimethyl-beta-alanine[no description available]medium10
aa 861[no description available]medium101,4-benzoquinones;
acetylenic compound;
primary alcohol		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
thromboxane b2[no description available]medium10thromboxanes Bhuman metabolite;
mouse metabolite
baicalein[no description available]medium10trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
bisindolylmaleimide i[no description available]medium10
16,16-dimethylprostaglandin f2alpha[no description available]medium10
lutein[no description available]medium10carotenolfood colouring;
plant metabolite
bumetanide[no description available]medium10amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
chlorine[no description available]medium30halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
rioprostil[no description available]medium10aliphatic alcohol
16,16-dimethylprostaglandin e[no description available]medium10prostanoid
carboprostacyclin[no description available]medium10prostanoid
morphine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
quinacrine[no description available]medium10acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
calcimycin[no description available]medium10benzoxazole
1-methyl-3-isobutylxanthine[no description available]medium203-isobutyl-1-methylxanthine
8-((4-chlorophenyl)thio)cyclic-3',5'-amp[no description available]medium103',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
aryl sulfide;
organochlorine compound		protein kinase agonist
cytarabine[no description available]medium10beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
zk 110841[no description available]medium10
adenosine-5'-(n-ethylcarboxamide)[no description available]medium10adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
adenosine diphosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
adenosine[no description available]medium10adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
ay 23626[no description available]medium10
xanthone[no description available]low00xanthonesinsecticide
2-Methoxyxanthone[no description available]low00xanthones
vadimezan[no description available]low00monocarboxylic acid;
xanthones		antineoplastic agent
psorospermin[no description available]low00epoxide;
organic heterotetracyclic compound;
xanthones		antineoplastic agent;
plant metabolite
8-deoxygartanin[no description available]low00xanthones
bellidifolin[no description available]low00polyphenol;
xanthones		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
metabolite
demethylbellidifolin[no description available]low00tetrol;
xanthones		antioxidant;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite;
mutagen;
radical scavenger
euxanthone[no description available]low00phenols;
xanthones		metabolite;
plant metabolite
gartanin[no description available]low00polyphenol;
xanthones		antineoplastic agent;
plant metabolite
gentiacaulein[no description available]low00aromatic ether;
polyphenol;
xanthones		plant metabolite
gentisein[no description available]low00polyphenol;
xanthones		plant metabolite
gentisin[no description available]low00aromatic ether;
polyphenol;
xanthones		plant metabolite
isogentisin[no description available]low00aromatic ether;
polyphenol;
xanthones		EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
mangiferin[no description available]low00C-glycosyl compound;
xanthones		anti-inflammatory agent;
antioxidant;
hypoglycemic agent;
plant metabolite
mangostin[no description available]low00aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
1,8-dihydroxy-3,7-dimethoxyxanthone[no description available]low00aromatic ether;
polyphenol;
xanthones		plant metabolite
norathyriol[no description available]low00polyphenol;
xanthones		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite
norlichexanthone[no description available]low00polyphenol;
xanthones		antimalarial;
fungal metabolite
norswertianolin[no description available]low00beta-D-glucoside;
xanthones		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite
swerchirin[no description available]low00aromatic ether;
phenols;
xanthones		hypoglycemic agent;
metabolite
1,2,8-trihydroxy-6-methoxyxanthone[no description available]low00aromatic ether;
polyphenol;
xanthones		antioxidant;
plant metabolite
isomangiferin[no description available]low00C-glycosyl compound;
polyphenol;
xanthones		anti-HSV-1 agent;
plant metabolite
macluraxanthone b[no description available]low00phenols;
xanthones		anti-HIV agent;
antineoplastic agent;
metabolite
lichexanthone[no description available]low00aromatic ether;
phenols;
xanthones		plant metabolite
decussatin[no description available]low00aromatic ether;
phenols;
xanthones		plant metabolite
gamma-mangostin[no description available]low00phenols;
xanthones		antineoplastic agent;
plant metabolite;
protein kinase inhibitor
1,7-dihydroxy-4-methoxyxanthone[no description available]low00aromatic ether;
phenols;
xanthones		metabolite;
plant metabolite
beta-Mangostin[no description available]low00xanthones
9-Hydroxycalabaxanthone[no description available]low00xanthones
nidulalin a[no description available]low00methyl ester;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
Penicillium metabolite
rubraxanthone[no description available]low00aromatic ether;
polyphenol;
xanthones		antibacterial agent;
antineoplastic agent;
metabolite
garcinone e[no description available]low00xanthones
2,3,6,8-tetrahydroxy-1-(3-methylbut-2-enyl)-5-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one[no description available]low00polyphenol;
xanthones		anti-inflammatory agent;
antineoplastic agent;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite
3-isomangostin[no description available]low00xanthones
2-[3-(4-morpholinyl)propylamino]-9-xanthenone[no description available]low00xanthones
garcinone c[no description available]low00xanthones
ConditionIndicatedRelationship StrengthStudiesTrials
Abdominal Migraine0low10
Absence Seizure0low10
Absence Seizures0low10
Ache0low10
Acute Confusional Migraine0low10
Acute Disease0low10
Acute Kidney Failure0low10
Acute Kidney Injury0low10
Acute Kidney Insufficiency0low10
Acute Renal Failure0low10
Acute Renal Injury0low10
Acute Renal Insufficiency0low10
Adenocarcinoma0low20
Adenocarcinoma Of Kidney0low10
Adenocarcinoma, Basal Cell0low20
Adenocarcinoma, Granular Cell0low20
Adenocarcinoma, Oxyphilic0low20
Adenocarcinoma, Renal0low10
Adenocarcinoma, Renal Cell0low10
Adenocarcinoma, Tubular0low20
Adenoma, Malignant0low20
Airflow Obstruction, Chronic0low10
Allodynia0low30
Allodynia, Mechanical0low30
Allodynia, Tactile0low30
Allodynia, Thermal0low30
Alloxan Diabetes0low10
Alveolitis, Fibrosing0low10
Anesthesia0low10
Angiogenesis, Pathologic0low40
Angiogenesis, Pathological0low40
Anoxemia0low10
Anoxia0low10
Anoxia, Brain0low10
Anoxia, Cerebral0low10
Anoxic Brain Damage0low10
Anoxic Encephalopathy0low10
Apoplexy0low10
Arthritis, Degenerative0low10
Arthroses0low10
Arthrosis0low10
Asthma0low20
Asthma, Bronchial0low20
Atherogenesis0low10
Atherosclerosis0low10
Atonic Absence Seizure0low10
Atonic Absence Seizures0low10
Atonic Seizure0low10
Atonic Seizures0low10
Bacterial Disease0low10
Bacterial Infection0low10
Bacterial Infections0low10
Benign Neoplasms0low10
Benign Neoplasms, Brain0low10
Blood Clot0medium11
Blood Pressure, High0low20
Brain Anoxia0low10
Brain Cancer0low10
Brain Concussion0low10
Brain Hypoxia0low10
Brain Inflammation0low10
Brain Metastases0low10
Brain Neoplasm, Primary0low10
Brain Neoplasms0low10
Brain Neoplasms, Benign0low10
Brain Neoplasms, Malignant0low10
Brain Neoplasms, Malignant, Primary0low10
Brain Neoplasms, Primary Malignant0low10
Brain Tumor, Primary0low10
Brain Tumor, Recurrent0low10
Brain Tumors0low10
Breast Cancer0low20
Breast Carcinoma0low20
Breast Neoplasms0low20
Breast Tumors0low20
Bronchial Asthma0low20
C gattii Infection0low10
C neoformans Infection0low10
C. gattii Infection0low10
C. neoformans Infection0low10
Cancer0low10
Cancer of Brain0low10
Cancer of Breast0low20
Cancer of Cervix0low10
Cancer of Colon0low10
Cancer of Endometrium0low10
Cancer of Kidney0low10
Cancer of Lung0low30
Cancer of Ovary0low20
Cancer of Pancreas0low30
Cancer of Skin0low10
Cancer of Stomach0low20
Cancer of the Brain0low10
Cancer of the Breast0low20
Cancer of the Cervix0low10
Cancer of the Colon0low10
Cancer of the Endometrium0low10
Cancer of the Kidney0low10
Cancer of the Lung0low30
Cancer of the Ovary0low20
Cancer of the Pancreas0low30
Cancer of the Skin0low10
Cancer of the Stomach0low20
Cancer of the Uterine Cervix0low10
Carcinoma0low20
Carcinoma of Endometrium0low10
Carcinoma, Anaplastic0low20
Carcinoma, Cribriform0low20
Carcinoma, Epidermoid0low10
Carcinoma, Granular Cell0low20
Carcinoma, Hypernephroid0low10
Carcinoma, Non-Small Cell Lung0low20
Carcinoma, Non-Small-Cell Lung0low20
Carcinoma, Planocellular0low10
Carcinoma, Renal Cell0low10
Carcinoma, Spindle-Cell0low20
Carcinoma, Squamous0low10
Carcinoma, Squamous Cell0low10
Carcinoma, Tubular0low20
Carcinoma, Undifferentiated0low20
Carcinomatosis0low20
Cell Transformation, Neoplastic0low10
Cerebral Anoxia0low10
Cerebral Concussion0low10
Cerebral Hypoxia0low10
Cerebral Stroke0low10
Cerebrovascular Accident0low10
Cerebrovascular Accident, Acute0low10
Cerebrovascular Apoplexy0low10
Cerebrovascular Stroke0low10
Cervical Cancer0low10
Cervical Migraine Syndrome0low10
Cervical Neoplasms0low10
Cervix Cancer0low10
Cervix Neoplasms0low10
Cholera Infantum0low10
Chromophil Renal Cell Carcinoma0low10
Chromophobe Renal Cell Carcinoma0low10
Chronic Airflow Obstruction0low10
Chronic Disease0low10
Chronic Hepatitis B0low10
Chronic Hepatitis B Virus Infection0low10
Chronic Illness0low10
Chronic Obstructive Airway Disease0low10
Chronic Obstructive Lung Disease0low10
Chronic Obstructive Pulmonary Disease0low10
Chronic Obstructive Pulmonary Diseases0low10
Chronically Ill0low10
Clear Cell Renal Carcinoma0low10
Clear Cell Renal Cell Carcinoma0low10
Clinically Isolated CNS Demyelinating Syndrome0low10
Clinically Isolated Syndrome, CNS Demyelinating0low10
Clonic Seizure0low10
Clonic Seizures0low10
COAD0low10
Colitis0low10
Collecting Duct Carcinoma0low10
Collecting Duct Carcinoma (Kidney)0low10
Collecting Duct Carcinoma of the Kidney0low10
Colon Cancer0low10
Colon Neoplasms0low10
Colonic Cancer0low10
Colonic Neoplasms0low10
Commotio Cerebri0low10
Communicable Diseases0low10
Complex Partial Seizure0low10
Complex Partial Seizures0low10
Concussion, Intermediate0low10
Concussion, Mild0low10
Concussion, Severe0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Convulsion0low10
Convulsion, Non-Epileptic0low10
Convulsions0low10
Convulsions, Grand Mal0low10
Convulsive Seizure0low10
Convulsive Seizures0low10
COPD0low10
Cough0low10
Cryptococcosis0low10
Cryptococcus gattii Infection0low10
Cryptococcus Infection0low10
Cryptococcus Infections0low10
Cryptococcus neoformans Infection0low10
Cryptogenic Tonic-Clonic Epilepsy0low10
CVA (Cerebrovascular Accident)0low10
Deficiency, Oxygen0low10
Degenerative Diseases, Central Nervous System0low10
Degenerative Diseases, Nervous System0low10
Degenerative Diseases, Neurologic0low10
Degenerative Diseases, Spinal Cord0low10
Degenerative Neurologic Diseases0low10
Degenerative Neurologic Disorders0low10
Demyelinating Diseases0low10
Demyelinating Disorders0low10
Demyelination0low10
Diabetes Mellitus0low10
Diabetes Mellitus, Experimental0low10
Disease Models, Animal0low80
Ectopic Ossification0low10
Encephalitis0low10
Encephalitis, Rasmussen0low10
Encephalopathy, Hypoxic0low10
Endometrial Cancer0low10
Endometrial Carcinoma0low10
Endometrial Neoplasms0low10
Endometrioma0low30
Endometriosis0low30
Endometrium Cancer0low10
Endotoxin Shock0low10
Envenomation, Scorpion0low10
Epilepsy, Grand Mal0low10
Epilepsy, Major0low10
Epilepsy, Tonic-Clonic0low10
Epilepsy, Tonic-Clonic, Cryptogenic0low10
Epilepsy, Tonic-Clonic, Familial0low10
Epilepsy, Tonic-Clonic, Symptomatic0low10
Epileptic Seizure0low10
Epileptic Seizures0low10
Epithelial Neoplasms, Malignant0low20
Epithelial Tumors, Malignant0low20
Epithelioma0low20
Equine Diseases0low10
Experimental Diabetes Mellitus0low10
Experimental Lung Inflammation0low10
Experimental Mammary Neoplasms0low10
Experimental Neoplasms0low10
Eye Diseases0low10
Eye Disorders0low10
Familial Tonic-Clonic Epilepsy0low10
Fever0low10
Fever, Zika0low10
Fibroses, Pulmonary0low10
Fibrosis, Pulmonary0low10
Functional Gastrointestinal Disorders0low10
Gastric Cancer0low20
Gastric Cancer, Familial Diffuse0low20
Gastric Neoplasms0low20
Gastrointestinal Diseases0low10
Gastrointestinal Disorders0low10
Gastrointestinal Disorders, Functional0low10
Generalized Absence Seizure0low10
Generalized Absence Seizures0low10
Generalized Tonic-Clonic Seizures0low10
Glial Cell Tumors0low10
Glioma0low10
Grand Mal Seizure Disorder0low10
Grawitz Tumor0low10
Group A Strep Infection0low10
Group A Streptococcal Infection0low10
Group A Streptococcal Infections0low10
Group B Strep Infection0low10
Group B Streptococcal Infection0low10
Group B Streptococcal Infections0low10
Headache, Migraine0low10
Hemicrania Migraine0low10
Hepatitis B Virus Infection, Chronic0low10
Hepatitis B, Chronic0low10
Heterotopic Ossification0low10
Horse Diseases0low10
Human Mammary Carcinoma0low20
Hyperalgesia0low30
Hyperalgesia, Mechanical0low30
Hyperalgesia, Primary0low30
Hyperalgesia, Secondary0low30
Hyperalgesia, Tactile0low30
Hyperalgesia, Thermal0low30
Hyperalgesic Sensations0low30
Hyperalgia0low30
Hyperalgia, Mechanical0low30
Hyperalgia, Primary0low30
Hyperalgia, Secondary0low30
Hyperesthesia0low10
Hyperesthesia, Tactile0low10
Hyperesthesia, Thermal0low10
Hyperesthetic Sensations0low10
Hyperhomocysteinemia0low10
Hypernephroma0low10
Hypertension0low20
Hypertension, Renal0low10
Hypoxemia0low10
Hypoxia0low10
Hypoxia, Brain0low10
Hypoxia, Cerebral0low10
Hypoxic Brain Damage0low10
Hypoxic Encephalopathy0low10
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0low10
Infection, Bacterial0low10
Infections, Bacterial0low10
Infections, Orthomyxoviridae0low10
Infections, Orthomyxovirus0low10
Infections, Streptococcal0low10
Infectious Diseases0low10
Inflammation0low60
Inflammation, Brain0low10
Innate Inflammatory Response0low60
Intestinal Diseases0low10
Intracranial Neoplasms0low10
Invasiveness, Neoplasm0low30
Jacksonian Seizure0low10
Kidney Cancer0low10
Kidney Failure, Acute0low10
Kidney Insufficiency, Acute0low10
Kidney Neoplasms0low10
Leucocythaemia0low10
Leucocythemia0low10
Leukemia0low10
Lobar Pneumonia0low10
Lung Cancer0low30
Lung Diseases, Obstructive0low10
Lung Inflammation0low10
Lung Neoplasms0low30
Major Motor Seizure Disorder0low10
Malignancy0low10
Malignant Epithelial Neoplasms0low20
Malignant Glioma0low10
Malignant Neoplasm of Breast0low20
Malignant Neoplasms0low10
Malignant Neoplasms, Brain0low10
Malignant Primary Brain Neoplasms0low10
Malignant Primary Brain Tumors0low10
Malignant Tumor of Breast0low20
Mammary Cancer0low20
Mammary Carcinoma, Human0low20
Mammary Neoplasm, Human0low20
Mammary Neoplasms, Experimental0low10
Mammary Neoplasms, Human0low20
Mechanical Allodynia0low30
Mechanical Hyperalgesia0low30
Migraine0low10
Migraine Disorders0low10
Migraine Headache0low10
Migraine Variant0low10
Mild Traumatic Brain Injury0low10
Mixed Glioma0low10
Muscle Contraction0low120
Muscle Relaxation0low70
Myoclonic Seizure0low10
Myoclonic Seizures0low10
Myopia, Degenerative0low10
Myopia, Pathological0low10
Myopia, Progressive0low10
Neoplasia0low10
Neoplasm0low10
Neoplasm Invasion0low30
Neoplasm Invasiveness0low30
Neoplasms0low10
Neoplasms, Benign0low10
Neoplasms, Brain0low10
Neoplasms, Brain, Benign0low10
Neoplasms, Brain, Malignant0low10
Neoplasms, Brain, Primary0low10
Neoplasms, Breast0low20
Neoplasms, Cervical0low10
Neoplasms, Cervix0low10
Neoplasms, Colonic0low10
Neoplasms, Endometrial0low10
Neoplasms, Experimental0low10
Neoplasms, Experimental Mammary0low10
Neoplasms, Gastric0low20
Neoplasms, Intracranial0low10
Neoplasms, Kidney0low10
Neoplasms, Lung0low30
Neoplasms, Malignant Epithelial0low20
Neoplasms, Ovarian0low20
Neoplasms, Pancreatic0low30
Neoplasms, Pulmonary0low30
Neoplasms, Skin0low10
Neoplasms, Stomach0low20
Neoplastic Cell Transformation0low10
Neoplastic Transformation, Cell0low10
Neovascularization, Pathologic0low40
Neovascularization, Pathological0low40
Nephroid Carcinoma0low10
Nervous System Degenerative Diseases0low10
Neurodegenerative Diseases0low10
Neurodegenerative Disorders0low10
Neurologic Degenerative Conditions0low10
Neurologic Degenerative Diseases0low10
Neurologic Diseases, Degenerative0low10
Non-Epileptic Seizure0low10
Non-Epileptic Seizures0low10
Non-Small Cell Lung Cancer0low20
Non-Small Cell Lung Carcinoma0low20
Non-Small-Cell Lung Carcinoma0low20
Nonepileptic Seizure0low10
Nonepileptic Seizures0low10
Nonsmall Cell Lung Cancer0low20
Obesity0low10
Obstructive Lung Diseases0low10
Obstructive Pulmonary Diseases0low10
Orthomyxoviridae Infections0low10
Orthomyxovirus Infections0low10
Ossification, Ectopic0low10
Ossification, Heterotopic0low10
Ossification, Pathologic0low10
Ossification, Pathological0low10
Osteoarthritis0low10
Osteoarthritis of Knee0low10
Osteoarthritis of the Knee0low10
Osteoarthritis, Knee0low10
Osteoarthrosis0low10
Osteoarthrosis Deformans0low10
Ovarian Cancer0low20
Ovarian Neoplasms0low20
Ovary Cancer0low20
Ovary Neoplasms0low20
Oxyesthesia0low10
Oxygen Deficiency0low10
Pain0low10
Pain, Burning0low10
Pain, Crushing0low10
Pain, Migratory0low10
Pain, Radiating0low10
Pain, Splitting0low10
Pancreas Cancer0low30
Pancreas Neoplasms0low30
Pancreatic Cancer0low30
Pancreatic Neoplasms0low30
Papillary Renal Cell Carcinoma0low10
Partial Seizure0low10
Partial Seizures0low10
Pathologic Angiogenesis0low40
Pathologic Neovascularization0low40
Pathologic Ossification0low10
Pelvic Pain0low10
Peritonitis0low20
Petit Mal Convulsion0low10
Pneumonia0low10
Pneumonia, Lobar0low10
Pneumonitis0low10
Pregnancy0low30
Primary Brain Neoplasms0low10
Primary Malignant Brain Neoplasms0low10
Primary Malignant Brain Tumors0low10
Primary Peritonitis0low20
Pulmonary Cancer0low30
Pulmonary Disease, Chronic Obstructive0low10
Pulmonary Fibroses0low10
Pulmonary Fibrosis0low10
Pulmonary Inflammation0low10
Pulmonary Neoplasms0low30
Pyrexia0low10
Rasmussen Encephalitis0low10
Rasmussen Syndrome0low10
Rasmussen's Syndrome0low10
Renal Cancer0low10
Renal Carcinoma0low10
Renal Cell Cancer0low10
Renal Cell Carcinoma0low10
Renal Cell Carcinoma, Papillary0low10
Renal Collecting Duct Carcinoma0low10
Renal Failure, Acute0low10
Renal Insufficiency, Acute0low10
Renal Neoplasms0low10
Sarcomatoid Renal Cell Carcinoma0low10
Schistosoma mansoni Infection0low10
Schistosomiasis mansoni0low10
Schistosomiasis, Intestinal0low10
Scorpion Envenoming0low10
Scorpion Stings0low10
Scorpionism0low10
Secondary Peritonitis0low20
Seizure0low10
Seizure Disorder, Grand Mal0low10
Seizure Disorder, Major Motor0low10
Seizure Disorder, Tonic Clonic0low10
Seizures0low10
Seizures, Auditory0low10
Seizures, Clonic0low10
Seizures, Convulsive0low10
Seizures, Epileptic0low10
Seizures, Focal0low10
Seizures, Generalized0low10
Seizures, Gustatory0low10
Seizures, Motor0low10
Seizures, Olfactory0low10
Seizures, Sensory0low10
Seizures, Somatosensory0low10
Seizures, Tonic0low10
Seizures, Tonic-Clonic0low10
Seizures, Vertiginous0low10
Seizures, Vestibular0low10
Seizures, Visual0low10
Septic Shock0low10
Shock, Endotoxic0low10
Shock, Septic0low10
Shock, Toxic0low10
Sick Headache0low10
Single Seizure0low10
Skin Cancer0low10
Skin Neoplasms0low10
Squamous Cell Carcinoma0low10
Status Migrainosus0low10
Stomach Cancer0low20
Stomach Neoplasms0low20
Streptococcal Infections0low10
Streptozocin Diabetes0low10
Streptozotocin Diabetes0low10
Stroke0low10
Stroke, Acute0low10
Suffering, Physical0low10
Swine Influenza0low10
Symptomatic Tonic-Clonic Epilepsy0low10
Tactile Allodynia0low30
Thermal Allodynia0low30
Thrombosis0medium11
Thrombus0medium11
Tonic Clonic Convulsions0low10
Tonic Clonic Seizure0low10
Tonic Seizure0low10
Tonic Seizures0low10
Tonic-Clonic Convulsion Disorder0low10
Tonic-Clonic Convulsion Syndrome0low10
Tonic-Clonic Seizure0low10
Tonic-Clonic Seizure Disorder0low10
Tonic-Clonic Seizure Syndrome0low10
Tonic-Clonic Seizures0low10
Torulosis0low10
Toxic Shock0low10
Toxic Shock Syndrome0low10
Transformation, Neoplastic Cell0low10
Tumorigenic Transformation0low10
Tumors0low10
Tumors, Breast0low20
Uterine Cervical Cancer0low10
Uterine Cervical Neoplasms0low10
Vascular Accident, Brain0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Long-term Use (2)

ArticleYear
EP4 receptor as a new target for bronchodilator therapy.
Thorax, Volume: 66, Issue: 12		2011
Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy.
American journal of respiratory and critical care medicine, Nov-15, Volume: 180, Issue: 10		2009
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (4)

ArticleYear
Thromboxane and isoprostane share the same prostanoid receptors to increase human placental tone.
Placenta, Volume: 32, Issue: 12		2011
Role of PGE(2) in protease-activated receptor-1, -2 and -4 mediated relaxation in the mouse isolated trachea.
British journal of pharmacology, Volume: 132, Issue: 1		2001
Blockade by ONO-NT-012, a unique prostanoid analogue, of prostaglandin E2-induced allodynia in conscious mice.
British journal of pharmacology, Volume: 115, Issue: 1		1995
Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP-receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea.
British journal of pharmacology, Volume: 99, Issue: 1		1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]